# One Molecule. Many Names. One Evidence Record.

> Research Peptide Fundamentals | Unbranded Peptides Review — Research Peptide Fundamentals research peptides: an independent guide to CJC-1295, semaglutide, tesamorelin, and PT-141 with names reconciled before evidence is counted.

**RESEARCH PEPTIDE FUNDAMENTALS / IDENTITY DESK**

A clinical-editorial guide to four peptide compounds, built to connect research codes, nonproprietary names, and formulations before studies are compared.

### [CJC-1295](/cjc-1295)

A GHRH-analog record in which the DAC and no-DAC distinction changes duration, interpretation, and identity.

### [Semaglutide](/semaglutide)

A GLP-1 receptor agonist with metabolic, cardiovascular, kidney, weight, and safety evidence under one generic name.

### [Tesamorelin](/tesamorelin)

A GHRH analogue with an approved HIV-lipodystrophy context and a study record that should not be generalized casually.

### [PT-141](/pt-141)

The research code for bremelanotide, a central melanocortin agonist whose evidence must be read by population and indication.

## Start with the name on the record

This site is a guide to four very different peptide compounds. The first task is not ranking them. It is making sure each paper belongs to the right molecule. A research code can later become a nonproprietary drug name. A short label can also hide two formulations that behave differently. If those identities are not reconciled, the same study may be counted twice, or a finding may be attached to the wrong form.

Unbranded Peptides Review treats naming as part of evidence quality. Each compound page begins with a plain description, then traces mechanism, human or preclinical findings, community-reported signals, and cautions. The comparison page keeps unlike evidence unlike. CJC-1295 and tesamorelin both address the growth-hormone-releasing pathway, but they are not substitutes. Semaglutide belongs to incretin research. PT-141 is bremelanotide and acts through central melanocortin signaling. The point is a cleaner reading of the record, not a shopping list or a treatment recommendation.

## The identity ledger

Evidence synthesis can fail before statistics begin. **CJC-1295** may mean the long-acting Drug Affinity Complex form, while “Modified GRF (1-29)” is often used for a short-acting no-DAC form. Their shared peptide backbone does not make their exposure profiles interchangeable; the albumin-binding design is central to the long-acting form [4][7]. **PT-141** is the research code attached to **bremelanotide**, so code-name and nonproprietary-name papers belong in one identity record when the compound is the same.

The same discipline applies to marketed medicines. **Semaglutide** is the nonproprietary name behind multiple products and formulations. A study of one population, route, or indication is not automatically evidence for every other one. **Tesamorelin** has a specific clinical context: its strongest trials concern excess abdominal fat in adults with HIV-associated lipodystrophy [13][15][17]. The ledger therefore records not only aliases, but formulation, population, comparator, duration, and outcome. Deduplication is not deletion. It is the work of counting one study once while retaining every relevant distinction.

## What are research peptides?

Peptides are short chains of amino acids, the same basic building blocks used to make proteins. Some act as signals: they bind a receptor and tell a cell to change what it is doing. “Research peptide” is not one regulatory category and does not mean every peptide has the same evidence or legal status. In this collection, the phrase spans an investigational GHRH analog, approved prescription medicines, and research-code terminology that remains common even after a nonproprietary name is established.

The mechanisms are equally diverse. CJC-1295 and tesamorelin engage the growth-hormone-releasing hormone receptor and influence the downstream GH/IGF-1 axis [1][16]. Semaglutide activates the GLP-1 receptor, affecting glucose-dependent insulin signaling, appetite circuits, and gastric emptying; large outcome trials address body weight, cardiovascular events, and kidney disease [9][10][11]. PT-141, or bremelanotide, acts chiefly through melanocortin receptors in neural circuits related to desire and arousal [19][20]. Calling all four “peptides” is chemically useful, but it says little about what they do, how mature their evidence is, or which safety questions matter.

## How this desk reads a study

Every entry is read in layers. First comes **identity**: exact compound, alias, and formulation. Next comes **setting**: cells, animals, healthy volunteers, or a defined patient population. Then comes **design**: review, analytical identification, randomized trial, extension study, or regulatory label. Finally comes **claim strength**: what the source measured, and what it did not.

That sequence prevents familiar errors. An animal mechanism does not prove a clinical benefit. A trial in adults with HIV-associated lipodystrophy does not establish general weight-loss use. A code-name paper should not be presented as separate corroboration when it studies the same drug later published under its nonproprietary name. Community experience is useful for seeing what people talk about, but it remains **anecdotal, not clinical evidence** and is labeled that way on the relevant pages. This desk reports approved status where the corpus supports it, but approval for one indication is not approval for every proposed use. The linked citations are the record; the prose is a map for reading it.

---

An independent identity-first digest of peptide literature—source reconciliation and study context, never a product desk or clinical directive.